Clinical and molecular characteristics in 83 cases of acute leukemia with AML1/ETO

Objective:To analyze the clinical and molecular characteristics of acute leukemia with AML1/ETO and explore the reasonable therapeutic principles.Method:Characteristics in morphology, immunology, molecular biology, cytogenetics, treatment and overall survival in 83 cases of acute leukemia with AML1/ETO were studied and analyzed. Result:Within 83 cases of acute leukemia with AML1/ETO, 17 cases(20.4%) had extramedullary infiltration, 47 cases(57.8%) with WBC count greater than 10×109/L, 45 cases(60.8%) with CD56 antigen positive, 29 cases(39.2%) with CD19 antigen positive. 65 patients had t(8;21) translocation which included 28 cases of t(8;21)translocation alone(43.1%), 37 cases(56.9%) with additional chromosome abnormality. All the 83 patients received induction chemotherapy and the overall CR rate was 79.5%, 17 patients relapsed within 6 months after CR in 66 patients who had achieved CR and the relapse rate was 25.9%. In 83 cases, 42 cases survived and 41 cases died, the median survival time was 26(range 2-113) months. 36 cases received allo-hematopoietic stem cell transplantation(HSCT), 25 cases survived and 3-year overall survival rate was 67.5%, 5-year overall survival rate was 56.6%. The 3-year overall survival rate was 36.4% in 47 patients who received chemotherapy. The analysis of prognosis factors showed that the patients’age and whether they express CD56 antigen or not had no statistical effect on overall survival, but the WBC count at the presentation, extramedullary infiltration, additional chromosome abnormality and treatment regimen (chemotherapy or transplantation) had statistical effects on overall survival. The overall survival in patients after HSCT was much higher than that in patients who received chemotherapy(P0.01).Conclusion:Acute leukemia patients with AML1/ETO would be prone to accompanied with high-risk factors, and HSCT could obviously improve the survival conditions of these patients.